Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Oregon: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 460 | 50% |
| 2020 | 12 | 469 | 51% |
| 2021 | 13 | 476 |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 76% of the cases CMS names in Oregon; 12 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 227 | 10,060+12%/yr | +12%/yr | 2.6 | 33% | 20,000 in 2030+12%/yr |
| Arizona | 106 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 32 | 1,588−2.2%/yr | −2.2%/yr | 4.01.0× | 3% | 1,810 in 2030+2.2%/yr |
| EP ablation |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Oregon · Every state · Compare with California
| 2024 |
| 718 |
| 59% |
| 2025 est. | ≈ 840 | – |
| 2026 est. | ≈ 930 | – |
| 53% |
| 2022 | 15 | 625 | 56% |
| 2023 | 20 | 786 | 58% |
| 2024 | 19 | 718 | 59% |
| 2025 from claims | – | 836 676–982 | 59% |
| 2026 forecast | – | 929 728–1,167 | 58% |
| 2027 forecast | – | 1,016 754–1,343 | 58% |
| 2028 forecast | – | 1,111 787–1,534 | 58% |
| 2029 forecast | – | 1,216 826–1,743 | 58% |
| 2030 forecast | – | 1,330 871–1,973 | 58% |
In 2025, 69% inpatient hospital, 26% hospital outpatient, 2% surgery center, 4% office. The share outside the hospital has moved +2 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~930 | ~650 | ~230 | ~18 | ~29 |
| 2027 · ~1,000 | ~720 | ~250 | ~21 | ~29 |
| 2028 · ~1,100 | ~790 | ~270 | ~24 | ~30 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 71% (69% in 2025), hospital outpatient about 24% (26% in 2025).
| 4,739+15%/yr |
| +15%/yr |
| 5.6 |
| 41% |
| 7,950 in 2030+9%/yr |
| Washington | 46 | 2,007+11%/yr | +11%/yr | 2.3 | 2% | 3,420 in 2030+9.3%/yr |
| Colorado | 39 | 1,871+12%/yr | +12%/yr | 3.3 | 4% | 4,220 in 2030+15%/yr |
| Idaho | 16 | 740+15%/yr | +15%/yr | 3.2 | 0% | 1,470 in 2030+12%/yr |
| Utah | 21 | 682+17%/yr | +17%/yr | 2.7 | 16% | 1,130 in 2030+8.9%/yr |
| Nevada | 14 | 673+17%/yr | +17%/yr | 2.0 | 16% | 1,740 in 2030+17%/yr |
| New Mexico | 5 | 431+11%/yr | +11%/yr | 1.6 | 2% | 1,040 in 2030+16%/yr |
| Montana | 12 | 395+13%/yr | +13%/yr | 1.9 | 0% | 760 in 2030+11%/yr |
| Alaska | 4 | 103+2.1%/yr | +2.1%/yr | 0.8 | 39% | 120 in 2030+2.5%/yr |
| 25 |
| 1,089+4.8%/yr |
| +4.8%/yr |
| 2.10.7× |
| 0% |
| 1,910 in 2030+9.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 74% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 4 companies reported engagement with Oregon’s surgeons worth $42K in consulting, speaking, meals and travel tied to these products, about $2,235 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.